Litvinov Ivan V, Abu-Hilal Mohannad, Alhusayen Raed, Delisle Bernard, Dutz Jan, Guénin Sophie, Ho Vincent, Kirchhof Mark G, Pehr Kevin, Roberge David
Division of Dermatology, McGill University, Montreal, QC, Canada.
Division of Dermatology, McMaster University, Hamilton, ON, Canada.
Front Med (Lausanne). 2024 Dec 16;11:1474030. doi: 10.3389/fmed.2024.1474030. eCollection 2024.
Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma (CTCL), representing the majority of all lymphomas arising in the skin. The disease treatment focuses on managing symptoms and preventing disease evolution. To date, there is no gold standard for MF-CTCL treatment. Chlormethine, a DNA alkylating agent, is a long-known treatment for CTCL. The new chlormethine 0.02% gel (CL-gel) formulation provides proven efficacy and ease of application, improving patient compliance and outcome. The current consensus paper and real-world experience with CL-gel in the treatment of early-stage MF-CTCL may help meet the unmet need for treatments in Canada. A modified Delphi process comprised a virtual meeting and an online follow-up. A panel of 9 board-certified dermatologists with expertise in cutaneous lymphoma and 1 radiation oncologist discussed the systematic literature review results, drew from clinical experience and the opinion of the panel to adopt and agree on five consensus statements. The panel shared real-world patient cases to illustrate the use of chlormethine gel in a variety of patients across Canada. Five real-world patient cases were provided to illustrate the panels' use of chlormethine gel.
蕈样肉芽肿（MF）是皮肤T细胞淋巴瘤（CTCL）最常见的类型，占所有皮肤淋巴瘤的大多数。该疾病的治疗重点是控制症状和预防疾病进展。迄今为止，MF-CTCL治疗尚无金标准。氮芥是一种DNA烷化剂，是一种早已为人所知的CTCL治疗方法。新型0.02%氮芥凝胶（CL-凝胶）制剂已证实具有疗效且使用方便，可提高患者的依从性和治疗效果。当前关于CL-凝胶治疗早期MF-CTCL的共识文件和实际应用经验可能有助于满足加拿大对该疾病治疗的未满足需求。一个经过改进的德尔菲流程包括一次虚拟会议和一次在线跟进。由9名具有皮肤淋巴瘤专业知识的皮肤科委员会认证专家和1名放射肿瘤学家组成的小组讨论了系统文献综述结果，借鉴临床经验并结合小组意见，采纳并商定了五条共识声明。该小组分享了实际患者案例，以说明氮芥凝胶在加拿大各类患者中的使用情况。提供了五个实际患者案例来说明该小组对氮芥凝胶的使用情况。
